» Articles » PMID: 38406150

Exploring the Relationship of Comorbidities, Smoking Status, HRCT Findings With COVID-19 Disease Severity and Outcomes

Overview
Journal Cureus
Date 2024 Feb 26
PMID 38406150
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Coronavirus disease 2019 (COVID-19) is a serious illness that can affect multiple organs including the lungs. The COVID-mortality risk is attributed to the quick transmission of the virus, the severity of disease, and preclinical risk factors, such as the presence of comorbidities. High-resolution computed tomography (HRCT) can predict disease severity in COVID-19 patients.

Methodology: This was a retrospective cohort study in which data were obtained from COVID centers at tertiary care hospitals in Azad Jammu and Kashmir. Details of clinical characteristics and HRCT findings along with details of smoking and comorbid history were obtained.

Results: Fever at hospital admission, HRCT findings, and having a partner predicted disease severity showed a significant p-value of <0.05. Old age and living in a combined household were associated with severe outcomes (p<0.05). Symptoms of shortness of breath (SOB) on hospital admission could predict the need for ICU admission in COVID-19 patients.

Conclusion: HRCT has a good predictive value for disease severity in patients with COVID-19, and old age is a risk factor. Although, limited associations were established in the analysis, in this study hyperlipidemia and hypertension significantly affected the course of disease. Further studies should be done to explore the relationship.

Citing Articles

Predictors of 2-year mortality in geriatric patients hospitalized with COVID-19 in Türkiye: a retrospective cohort study.

Bektan Kanat B, Avci G, Bayramlar O, Suzan V, Can G, Balkan I Biomark Med. 2024; 18(10-12):555-565.

PMID: 39140394 PMC: 11364071. DOI: 10.1080/17520363.2024.2352416.

References
1.
Callender L, Curran M, Bates S, Mairesse M, Weigandt J, Betts C . The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. Front Immunol. 2020; 11:1991. PMC: 7437504. DOI: 10.3389/fimmu.2020.01991. View

2.
Logie C, Coelho M, Kohrt B, Tsai A, Mendenhall E . Context, COVID-19 and comorbidities: exploring emergent directions in syndemics and HIV research. Curr Opin HIV AIDS. 2022; 17(2):46-54. PMC: 11045292. DOI: 10.1097/COH.0000000000000722. View

3.
Zhao Y, Shi L, Jiang Z, Zeng N, Mei H, Lu Y . The phenotype and prediction of long-term physical, mental and cognitive COVID-19 sequelae 20 months after recovery, a community-based cohort study in China. Mol Psychiatry. 2023; 28(4):1793-1801. PMC: 9869317. DOI: 10.1038/s41380-023-01951-1. View

4.
Le Guen C, Muir K, Simons M, Coffman D, Soans R . The Impact of Smoking Status and Smoking-Related Comorbidities on Coronavirus Disease 2019 Patient Outcomes: A Causal Mediation Analysis. Nicotine Tob Res. 2022; 25(2):331-338. PMC: 9384707. DOI: 10.1093/ntr/ntac193. View

5.
Du H, Pan X, Liu N, Chen J, Chen X, Werring D . The effect of vascular risk factor burden on the severity of COVID-19 illness, a retrospective cohort study. Respir Res. 2020; 21(1):241. PMC: 7503438. DOI: 10.1186/s12931-020-01510-0. View